HCTI

Healthcare Triangle, Inc.
CAPPED RATING

Healthcare Triangle, Inc., a healthcare information technology company, focuses on developing solutions in the sectors of cloud services, data science, and professional and managed services. It provides a suite of software, solutions, platforms, and services that enables healthcare and pharma organizations to deliver personalized healthcare, precision medicine, advances in drug discovery, development and efficacy, collaborative research and development, respond to evidence, and enhance the digital transformation. The company's software platforms include CloudEz, an enterprise multi-cloud transformation and management platform that enables customers to manage their cloud infrastructure across private, hybrid, and public cloud infrastructures; and DataEz, a cloud-based data analytics and data science platform for the data analytics and data science requirements of life sciences/pharmaceutical and healthcare provider organizations. It also provides Readabl.AI, a Software-as-a-Service solution that uses public cloud artificial intelligence and machine learning to recognize and extract healthcare information from documents, faxes, and narrative reports. In addition, it offers cloud IT services; and healthcare IT services, such as electronic health records and software implementation, optimization, and extension to community partners, as well as application managed services, and backup and disaster recovery on public cloud. The company primarily serves healthcare delivery organizations, healthcare insurance companies, pharmaceutical and life sciences, biotech companies, and medical device manufacturers. Healthcare Triangle, Inc. was incorporated in 2019 and is based in Pleasanton, California. Healthcare Triangle, Inc. operates as a subsidiary of SecureKloud Technologies, Inc.

Healthcare Triangle, Inc. (HCTI) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B); its weakest is Momentum (F). The rating has held at C for 7 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.4 / 5.0
C
Value
B-
Factor Score 3.0 / 5.0
Growth
B
Factor Score 3.5 / 5.0
Profitability
C+
Factor Score 2.5 / 5.0
Momentum
F
Factor Score 0.3 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -5.6
EV / EBITDA -3.0
Rev Growth YoY 158.4%
Gross Margin 21.5%
Price Return 3M -87.3%
Price Return 12M -99.9%
Catalyst Signal 0.00
Market Cap $3.9M
TTM Revenue $25.7M
Price / Sales 0.2
ROE -57.4%

Historical Factor Score Progression

Held C for 7 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 B- (3.0) B (3.5) C+ (2.5) F (0.3) C+ (2.6) C (2.4)
2026-11-05 B- (3.0) B (3.5) C+ (2.6) F (0.4) C+ (2.7) C (2.4)
2026-10-29 B- (3.0) B (3.5) C+ (2.6) F (0.5) C+ (2.7) C (2.4)
2026-10-22 B- (3.0) B (3.5) C+ (2.6) F (0.4) C+ (2.6) C (2.4)
2026-10-15 B- (3.0) B (3.5) C+ (2.6) F (0.4) C+ (2.6) C (2.4)
Page 1 of 4